DoD Gulf War Illness, Clinical Evaluation Award | W81XWH 20 GWIRP CEA

Opportunity Information: Apply for W81XWH 20 GWIRP CEA

The Department of Defense Gulf War Illness Research Program (GWIRP) Clinical Evaluation Award (FY20) is designed to move the most solid Gulf War Illness (GWI) research closer to real-world use by testing it directly in Gulf War Veteran populations. The opportunity sits in the "Verification" stage of the GWIRP research pipeline, meaning it is not aimed at early discovery work but at evaluating and confirming findings that already have meaningful supporting evidence. In practice, this includes translating validated GWI research and qualified, replicated preclinical results into clinical evaluation studies that can show whether proposed biomarkers or interventions hold up when tested with Veterans who have GWI.

A major priority for this award is clinical biomarker work that is statistically powered and capable of validating biomarkers as clinical endpoints. This includes large-scale clinical biomarker studies and biomarker trials that can help determine whether measurable biological indicators can reliably track disease status, subgroup patients, or reflect response to treatment. The award also encourages proof-of-concept intervention trials, such as pilot studies, first-in-human efforts, or Phase I to early Phase IIa trials. Treatments repurposed from other disorders with overlapping symptoms may be considered, but the program preference is clearly toward projects that build on results generated within the GWI research community and that translate already qualified findings rather than starting from scratch.

A non-negotiable requirement is that award funds must support research conducted in a Gulf War Veteran population. Applicants also have to provide evidence that they can actually access the needed Veteran cohort(s) and any critical reagents or resources required to complete the study, which is essentially meant to prevent proposals that look good on paper but cannot recruit or execute. The program also points applicants to DoD-provided outreach and recruitment best practices for engaging Gulf War Veterans, signaling that recruitment feasibility and Veteran-centered practices are taken seriously in review.

The Areas of Emphasis reflect the program's strong interest in clinically translating both treatments and biological indicators/targets tied to dysregulated system function. The opportunity highlights a wide range of symptom domains commonly seen in GWI, including cognitive problems (memory deficits, mood and behavioral disturbances), non-restorative sleep and sleep disruption, chronic widespread pain, severe fatigue, gastrointestinal problems (including dietary intolerances, GERD, and functional GI disorders), sinus and respiratory issues, headaches, dermatological conditions, and neurological dysfunction spanning central, peripheral, autonomic, and neuromuscular systems. It also calls out immune dysfunction, endocrine/exocrine/excretory dysfunction with particular attention to kidney and liver issues (including Cytochrome P450 abnormalities), microbiome variants, and the way stressors like exertion or immune challenge can worsen symptoms. Another emphasized concept is "disordered system crosstalk," such as immune disruption affecting the nervous system or autonomic dysfunction altering GI function, with the larger goal of understanding why multiple physiological systems may be affected at once. Beyond symptom-focused research, the announcement highlights interest in validating molecular signatures (genomic, proteomic, metabolic, epigenetic) that may underlie symptoms and could help define biologically meaningful subgroups, as well as investigating comorbidities, mortality, and differences by sex or ethnicity. While the announcement lists these priorities, it also makes clear applicants can propose other GWI-relevant clinical evaluation studies aligned with the GWIRP mission and overarching challenges.

Two collaboration-oriented options can increase the allowable budget if the project meets additional requirements. The Biorepository Contribution Option encourages applicants to contribute Gulf War Veteran biospecimens and associated data to the established Boston Biorepository, Recruitment, and Integrative Network (BBRAIN) for GWI, which is intended to support long-term sharing and reuse of specimens and data across the field. Separately, the Clinical Consortium Collaboration Option encourages investigators to use the infrastructure of the Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC), such as recruitment networks, established protocols, Common Data Elements, and data management procedures. This consortium option requires a letter of collaboration from GWICTIC describing what resources or services will be shared and how that adds value. Importantly, if an applicant uses the consortium collaboration option, they cannot also apply under the biorepository contribution option, because consortium projects must follow GWICTIC policies on biospecimens and data.

The announcement also spells out what it will not fund. It does not support studies that treat psychiatric disease or psychological stress as the primary cause of GWI, nor does it support implementing care guidelines that heavily emphasize psychiatric pathologies or psychiatric remedies. It also does not support applications focused on amyotrophic lateral sclerosis (ALS) as a main topic, although Veterans with ALS can be included if ALS is part of the study's GWI case definition and the research remains focused on GWI symptomatology. Applicants who want to do ALS-focused work are directed to the separate ALS Research Program.

From a funding and administrative standpoint, awards are made as assistance agreements, meaning either grants or cooperative agreements depending on how much involvement the DoD anticipates having during the project. If there is no substantial agency involvement, the mechanism is a grant; if substantial involvement is expected (for example, collaboration or participation in aspects of the research), it becomes a cooperative agreement. For budgeting, anticipated direct costs for the entire performance period are capped at $1.5 million for the standard award, up to $1.52 million with the Biorepository Contribution Option, and up to $1.7 million with the Clinical Consortium Collaboration Option. The Department of Defense indicated it expected to allocate about $4.8 million total to support roughly two awards, with final funding dependent on federal appropriations, application volume, and scientific and programmatic review outcomes.

Key dates and logistics are also clearly stated in the source information. The opportunity (W81XWH-20-GWIRP-CEA) was posted March 24, 2020 and had an original closing date of September 10, 2020. Awards were expected to be made no later than September 30, 2021. The funding was expected to be drawn from FY20 funds, which were anticipated to remain available for use until September 30, 2026, shaping the practical window for spending and project execution planning. Eligible applicants were described as unrestricted (open to any entity type, subject to any additional eligibility clarifications in the full announcement), and the administering agency was the Department of Defense, Department of the Army, USAMRAA, under CFDA 12.420.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Gulf War Illness, Clinical Evaluation Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 24, 2020.
• Applicants must submit their applications by Sep 10, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 20 GWIRP CEA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: